Industrial preparations of natural killer (NK) cells and injections containing NK cells
US10125351B2 · kind B2 · utility
Inventors
Key dates
| Filing date | Dec 19, 2012 |
| Grant date | Nov 13, 2018 |
| Priority date | — |
| Expiry date | Dec 19, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/515
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An industrial preparation of natural killer cells (NKs) is produced by: using umbilical cord blood and peripheral blood from legitimate sources as raw materials, obtaining stem cells by a method for extracting and separating karyocytes, or using FICOLL® or PERCOLL® density gradient media centrifugation to isolate and screen out karyocytes; diluting the above-mentioned karyocytes with cell culture medium, adding interferon, interleukin, CD3 antibody, and human albumin, loading them together into a bioreactor for perfusion culture, and then performing multiplication culture; the passage number of natural killer cells from multiplication culture is no less than 8, and the culture time is no less than 4 weeks; the markers of the natural killer cells obtained after the multiplication culture are CD3−\CD56+, CD16+, CD57+, and CD8+, wherein CD16+/CD56+≥15%, CD3−/CD56+≥50%, and CD8+/CD57+≥8%; then preparing an injection with a certain concentration using the cell suspension obtained by above-mentioned method.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.